American Heart Journal
Volume 148, Issue 6 , Pages 1003-1006 , December 2004

GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention

  • Jose E. Exaire, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Sorin J. Brener, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Jay S. Yadav, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Deepak L. Bhatt, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA.

Received 15 March 2004 ,Accepted 23 June 2004.

References 

  1. Heusch G, Schulz R, Baumgart D, et al.  Coronary microembolization. Prog Cardiovasc Dis. 2001;44:217–230
  2. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570–580
  3. Stone GW, Rogers C, Ramee S, et al.  Distal filter protection during saphenous vein graft stenting (technical and clinical correlates of efficacy). J Am Coll Cardiol. 2002;40:1882–1888
  4. Stone GW, Rogers C, Hermiller J, et al.  Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003;108:548–553
  5. Baim DS, Wahr D, George B, et al.  Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285–1290
  6. Michaels AD, Appleby M, Otten MH, et al.  Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions (results of the randomized, controlled Vasodilator Prevention on No-reflow (VAPOR) trial). J Invasive Cardiol. 2002;14:299–302
  7. Gibson CM, Cannon CP, Murphy SA, et al.  Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909–1913
  8. Gibson CM, Cannon CP, Murphy SA, et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–130
  9. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–763
  10. Kearney M, Pieczek A, Haley L, et al.  Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997;95:1998–2002
  11. Dangas G, Mehran R, Lansky AJ, et al.  Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. Am J Cardiol. 2000;86:777–779 , A6
  12. Roffi M, Mukherjee D, Chew DP, et al.  Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts (a pooled analysis of five randomized clinical trials). Circulation. 2002;106:3063–3067
  13. Bhatt DL, Topol EJ. Percutaneous coronary intervention for patients with prior bypass surgery (therapy in evolution). Am J Med. 2000;108:176–177
  14. Sdringola S, Assali AR, Ghani M, et al.  Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 2001;54:318–324
  15. Sdringola S, Assali A, Ghani M, et al.  Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51:394–399
  16. Ellis SG, Chew D, Chan A, et al.  Death following creatine kinase-MB elevation after coronary intervention (identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy). Circulation. 2002;106:1205–1210
  17. Kini A, Marmur JD, Kini S, et al.  Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course (implications for early discharge after coronary intervention). J Am Coll Cardiol. 1999;34:663–671
  18. Oh JK, Shub C, Ilstrup DM, et al.  Creatine kinase release after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1985;109:1225–1231
  19. Abdelmeguid AE, Ellis SG, Sapp SK, et al.  Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097–1105
  20. Dillon MC, Calbreath DF, Dixon AM, et al.  Diagnostic problem in acute myocardial infarction (CK-MB in the absence of abnormally elevated total creatine kinase levels). Arch Intern Med. 1982;142:33–38

PII: S0002-8703(04)00410-7

doi: 10.1016/j.ahj.2004.06.015

American Heart Journal
Volume 148, Issue 6 , Pages 1003-1006 , December 2004

Article Tools